Jul 28, 2017
Alkaloid marked 9% growth in consolidated sales, 11% growth in consolidated net profit, sales in Great Britain in amount of mkd 127.9 million and 54 new employments in the period January - June 2017
Alkaloid marked 9% growth in consolidated sales, 11% growth in consolidated net profit, sales in Great Britain in amount of mkd 127.9 million and 54 new employments in the period January - June 2017
Alkaloid AD Skopje achieved positive financial results in the period January-June 2017 - shows the unaudited standalone and unaudited consolidated Income Statement.
According to the unaudited standalone Income Statement, in the period January- June the sales reached the amount of MKD 3,507,290,746 - 8% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 649,689,157 marked an increase of roughly 11%, whereas the net profit amounting to MKD 374,886,745 rose by 9%.
In the period January – June the total consolidated sales reached MKD 4,554,009,259 – an increase of 9% compared to the same period last year. Consolidated sales in the domestic market increased by 7%, while the total consolidated export of the company increased by 10%. Out of the total consolidated sales, 39% were realized in the domestic market, while the foreign markets account for 61%. The breakdown by region shows that the countries of South-East Europe account for 32% of the sales, Russia and CIS – 7%, 21% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 1% of the total consolidated sales. Noticeable rise was seen in Great Britain reaching sales of MKD 127,873,079 and Hungary with sales of MKD 11,691,735 – both increased by 18 times compared to the same period last year. Growth in sales was also marked in the following export markets: Russia – 24%, Romania – 52%, Slovenia - 24%, Ukraine - 33%, Montenegro – 17% etc.
The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals – 84%, with OTC products accounting for 21%, cardiovascular products - 16%, antibiotics - 14%, neurological products – 13% etc. The Chemistry Cosmetics Botanicals segment accounts for 16% of the total consolidated sales, or more precisely Chemistry – 3%, Cosmetics – 10% and Botanicals – 3%.
Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 668,995,343 saw an increase of 12%, whereas the net consolidated profit amounting to MKD 361,750,584 went up by 11%.
The total investments in non-current assets for the period January – June 2017 amounted to MKD 323,470,022.
In the period January – June 2017 Alkaloid recruited 54 new employees in the Republic of Macedonia.